Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML0173

Sigma-Aldrich

Reversan

≥98% (HPLC)

Synonym(e):

CBLC4H10, N-[3-(4-Morpholinyl)propyl]-5,7-diphenyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C26H27N5O2
CAS-Nummer:
313397-13-6
Molekulargewicht:
441.52
MDL-Nummer:
MFCD01528184
UNSPSC-Code:
12161501
PubChem Substanz-ID:
329825203
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

powder

Farbe

faintly yellow to yellow

Löslichkeit

DMSO: ≥8 mg/mL at ~60 °C

Lagertemp.

2-8°C

SMILES String

O=C(NCCCN1CCOCC1)c2cnn3c(cc(nc23)-c4ccccc4)-c5ccccc5

InChI

1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32)

InChIKey

JTRXWCLQFAZHGP-UHFFFAOYSA-N

Anwendung

Reversan may be used in cell signaling studies.

Biochem./physiol. Wirkung

Nontoxic MRP1 function inhibitor; MRP1 and Pgp function inhibitor; multidrug transporter inhibitor
Reversan increases the efficacy of vincristine and etoposide and increases the sensitivity of murine models of neuroblastoma to conventional chemotherapy.
Reversan is a selective and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp) inhibitor.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
101M4615V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Catherine A Burkhart et al.
Cancer research, 69(16), 6573-6580 (2009-08-06)
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine
Michelle J Henderson et al.
Journal of the National Cancer Institute, 103(16), 1236-1251 (2011-07-30)
Although the prognostic value of the ATP-binding cassette, subfamily C (ABCC) transporters in childhood neuroblastoma is usually attributed to their role in cytotoxic drug efflux, certain observations have suggested that these multidrug transporters might contribute to the malignant phenotype independent
Katharina Esser-Nobis et al.
Hepatology (Baltimore, Md.), 62(2), 397-408 (2015-04-14)
Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper
Frank Loganzo et al.
Molecular cancer therapeutics, 14(4), 952-963 (2015-02-04)
Antibody-drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.